{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:29:43Z","timestamp":1793852983067,"version":"4.6.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1038\/s41433-021-01421-4","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T22:00:19Z","timestamp":1613167219000},"page":"1574-1586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Headache for ophthalmologists: current advances in headache understanding and management"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6314-4437","authenticated-orcid":false,"given":"Susan P.","family":"Mollan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0679-9696","authenticated-orcid":false,"given":"Jasvir S.","family":"Virdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Bilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Thaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Krishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"1421_CR1","unstructured":"WHO. Headache Disorders 2016. [Internet]. World Health Organisation. [updated 8 April 2016; cited 24 May 2020]. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/headache-disorders."},{"key":"1421_CR2","first-page":"354","volume":"7","author":"R Jensen","year":"2008","unstructured":"Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Neurology. 2008;7:354\u201361.","journal-title":"Neurology"},{"key":"1421_CR3","unstructured":"WHO. Atlas of headache disorders and resources in the world 2011. [Internet]. World Health Organisation. [updated 2011; cited 24 May 2020]. https:\/\/www.who.int\/mental_health\/management\/atlas_headache_disorders\/en\/."},{"key":"1421_CR4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"VL Feigin","year":"2019","unstructured":"Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459\u201380.","journal-title":"Lancet Neurol"},{"key":"1421_CR5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1212\/01.wnl.0000323925.29520.e7","volume":"71","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population. Neurology. 2008;71:559\u201366.","journal-title":"Neurology"},{"key":"1421_CR6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barr\u00e9 J, Katsarava Z, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19:703\u201311.","journal-title":"Eur J Neurol"},{"key":"1421_CR7","first-page":"1","volume":"363","author":"SP Mollan","year":"2018","unstructured":"Mollan SP, Spitzer D, Nicholl DJ. Raised intracranial pressure in those presenting with headache. BMJ. 2018;363:1\u20135.","journal-title":"BMJ"},{"key":"1421_CR8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/WCO.0000000000000651","volume":"32","author":"SP Mollan","year":"2018","unstructured":"Mollan SP, Hoffmann J, Sinclair AJ. Advances in the understanding of headache in idiopathic intracranial hypertension. Curr Opin Neurol. 2018;32:92\u20138.","journal-title":"Curr Opin Neurol"},{"key":"1421_CR9","first-page":"1","volume":"38","author":"M Vincent","year":"2018","unstructured":"Vincent M, Wang S. Headache classification committee of the international headache society (ihs) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","journal-title":"Cephalalgia"},{"key":"1421_CR10","unstructured":"National Institute for Health and Care Excellence. Headaches in over 12s: diagnosis and management. [London]: NICE; 2018. (Clinical guideline [CG150])."},{"key":"1421_CR11","unstructured":"BASH. National headache management system for adults 2019. British Association for the Study of Headache guidelines; 2019. http:\/\/www.bash.org.uk\/downloads\/guidelines2019\/01_BASHNationalHeadache_Management_SystemforAdults_2019_guideline_versi.pdf"},{"key":"1421_CR12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/brain\/awn321","volume":"132","author":"PJ Goadsby","year":"2009","unstructured":"Goadsby PJ. The vascular theory of migraine\u2014a great story wrecked by the facts. Brain. 2009;132:6\u20137.","journal-title":"Brain"},{"key":"1421_CR13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553\u2013622.","journal-title":"Physiol Rev"},{"key":"1421_CR14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","volume":"18","author":"M Ashina","year":"2019","unstructured":"Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol. 2019;18:795\u2013804.","journal-title":"Lancet Neurol"},{"key":"1421_CR15","unstructured":"Greenburg D, Aminoff M, Simon R. Headache and facial pain. Clin Neurol. 8th ed., McGraw Hill Professional: 2012."},{"key":"1421_CR16","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.4103\/0972-2327.99993","volume":"15","author":"P Goadsby","year":"2012","unstructured":"Goadsby P. Pathophysiology of migraine. Ann Indian Acad Neurol. 2012;15:S15\u201322.","journal-title":"Ann Indian Acad Neurol"},{"key":"1421_CR17","unstructured":"NICE CKS. Headache\u2014assessment 2016. [Internet]. NICE; [updated 2019 October; cited 24 May 2020]. https:\/\/cks.nice.org.uk\/headache-assessment#!scenariorecommendation:1."},{"key":"1421_CR18","first-page":"550","volume":"3","author":"DW Dodick","year":"2003","unstructured":"Dodick DW. Clinical clues and clinical rules: primary vs secondary headache. Adv Stud Med. 2003;3:550\u20135.","journal-title":"Adv Stud Med"},{"key":"1421_CR19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1212\/WNL.0000000000006697","volume":"92","author":"TP Do","year":"2019","unstructured":"Do TP, Remmers A, Schytz HW, Schankin C, Nelson SE, Obermann M, et al. Red and orange flags for secondary headaches in clinical practice. Neurology. 2019;92:134\u201344.","journal-title":"Neurology"},{"key":"1421_CR20","first-page":"547","volume":"339","author":"Z Morris","year":"2009","unstructured":"Morris Z, Whiteley WN, Longstreth WT, Weber F, Lee YC, Tsushima Y, et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2009;339:547\u201350.","journal-title":"BMJ"},{"key":"1421_CR21","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00415-016-8189-x","volume":"263","author":"EJ Volkers","year":"2016","unstructured":"Volkers EJ, Donders RC, Koudstaal PJ, van Gijn J, Algra A, Jaap Kappelle L. Transient monocular blindness and the risk of vascular complications according to subtype: a prospective cohort study. J Neurol. 2016;263:1771\u20137.","journal-title":"J Neurol"},{"key":"1421_CR22","doi-asserted-by":"publisher","unstructured":"Lyons HS, Quick V, Sinclair AJ, Nagaraju S, Mollan SP. A new era for giant cell arteritis. Eye. 2019; e-pub ahead of print 3 October 2019; https:\/\/doi.org\/10.1038\/s41433-019-0608-7.","DOI":"10.1038\/s41433-019-0608-7"},{"key":"1421_CR23","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01093-7","volume":"21","author":"SP Mollan","year":"2020","unstructured":"Mollan SP, Paemeleire K, Versijpt J, Luqmani R, Sinclair AJ. European Headache Federation recommendations for neurologists managing giant cell arteritis. J Headache Pain. 2020;21:28.","journal-title":"J Headache Pain"},{"key":"1421_CR24","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1161\/STROKEAHA.112.656603","volume":"43","author":"T Kurth","year":"2012","unstructured":"Kurth T, Diener HC. Migraine and stroke: perspectives for stroke physicians. Stroke. 2012;43:3421\u20136.","journal-title":"Stroke"},{"key":"1421_CR25","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/practneurol-2014-000821","volume":"14","author":"SP Mollan","year":"2014","unstructured":"Mollan SP, Markey KA, Benzimra JD, Jacks A, Matthews TD, Burdon MA, et al. A practical approach to, diagnosis, assessment and management of idiopathic intracranial hypertension. Pract Neurol. 2014;14:380\u201390.","journal-title":"Pract Neurol"},{"key":"1421_CR26","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/jnnp-2015-311302","volume":"87","author":"SP Mollan","year":"2016","unstructured":"Mollan SP, Ali F, Hassan-Smith G, Botfield H, Friedman DI, Sinclair AJ. Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management. J Neurol Neurosurg Psychiatry. 2016;87:982\u201392.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1421_CR27","first-page":"101","volume":"9","author":"JA Opara","year":"2016","unstructured":"Opara JA, Brola W, Wylegala AA, Wylegala E. Uhthoff\u2019s phenomenon 125 years later - what do we know today? J Med Life. 2016;9:101\u20135.","journal-title":"J Med Life"},{"key":"1421_CR28","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/1352458511431074","volume":"18","author":"CL Fraser","year":"2012","unstructured":"Fraser CL, Davagnanam I, Radon M, Plant GT. (2012). The time course and phenotype of Uhthoff phenomenon following optic neuritis. Mult Scler. 2012;18:1042\u20132.","journal-title":"Mult Scler"},{"key":"1421_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.12946","volume":"57","author":"CJ Schankin","year":"2017","unstructured":"Schankin CJ, Viana M, Goadsby PJ. Persistent and repetitive visual disturbances in migraine: a review. Headache. 2017;57:1\u201316.","journal-title":"Headache"},{"key":"1421_CR30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/practneurol-2019-002460","volume":"20","author":"J Virdee","year":"2020","unstructured":"Virdee J, Mollan SPPhotopsia. Pract Neurol. 2020;20:415\u20139.","journal-title":"Pract Neurol"},{"key":"1421_CR31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1528-1157.2001.080876.x","volume":"42","author":"H Muranaka","year":"2001","unstructured":"Muranaka H, Fujita H, Goto A, Osari SI, Kimura Y. Visual symptoms in epilepsy and migraine: localization and patterns. Epilepsia. 2001;42:62\u20136.","journal-title":"Epilepsia"},{"key":"1421_CR32","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/j.pain.0000000000001421","volume":"160","author":"M Vila-Pueyo","year":"2019","unstructured":"Vila-Pueyo M, Strother LC, Kefel M, Goadsby PJ, Holland PR. Divergent influences of the locus coeruleus on migraine pathophysiology. Pain. 2019;160:385\u201394.","journal-title":"Pain"},{"key":"1421_CR33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/head.12572","volume":"55","author":"FH Maniyar","year":"2015","unstructured":"Maniyar FH, Sprenger T, Monteith T, Schankin CJ, Goadsby PJ. The premonitory phase of migraine\u2014what can we learn from it? Headache. 2015;55:609\u201320.","journal-title":"Headache"},{"key":"1421_CR34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41582-018-0098-4","volume":"14","author":"N Karsan","year":"2018","unstructured":"Karsan N, Goadsby PJ. Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol. 2018;14:699\u2013710.","journal-title":"Nat Rev Neurol"},{"key":"1421_CR35","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1212\/CON.0000000000000626","volume":"24","author":"P Bose","year":"2018","unstructured":"Bose P, Karsan N, Goadsby PJ. The Migraine Postdrome. Contin Lifelong Learn Neurol. 2018;24:1023\u201331.","journal-title":"Contin Lifelong Learn Neurol"},{"key":"1421_CR36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1212\/WNL.0000000000002789","volume":"87","author":"NJ Giffin","year":"2016","unstructured":"Giffin NJ, Lipton RB, Silberstein SD, Olesen J, Goadsby PJ. The migraine postdrome. Neurology. 2016;87:309\u201313.","journal-title":"Neurology"},{"key":"1421_CR37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1468-2982.1992.1204221.x","volume":"12","author":"BK Rasmussen","year":"1992","unstructured":"Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia. 1992;12:221\u20138.","journal-title":"Cephalalgia"},{"key":"1421_CR38","unstructured":"Migraine Editorial Team. Aura. [Internet]. Migraine.com; [updated 2010 November; cited 2 June 2020]. https:\/\/migraine.com\/migraine-symptoms\/aura\/."},{"key":"1421_CR39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jama.296.3.283","volume":"296","author":"T Kurth","year":"2006","unstructured":"Kurth T, Gaziano J, Logroscino NRC, Diener G. H, JE B. Migraine and risk of cardiovascular disease in women. JAMA. 2006;296:283\u201391.","journal-title":"JAMA"},{"key":"1421_CR40","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.4103\/0972-2327.100015","volume":"15","author":"AJ Sinclair","year":"2012","unstructured":"Sinclair AJ, Matharu M. Migraine, cerebrovascular disease and the metabolic syndrome. Ann Indian Acad Neurol. 2012;15:S72\u20137.","journal-title":"Ann Indian Acad Neurol"},{"key":"1421_CR41","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/jnnp-2018-318254","volume":"91","author":"LR \u00d8ie","year":"2020","unstructured":"\u00d8ie LR, Kurth T, Gulati S, Dodick DW. Migraine and risk of stroke. J Neurol Neurosurg Psychiatry. 2020;91:593\u2013604.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1421_CR42","first-page":"55","volume":"3","author":"AG Edlow","year":"2010","unstructured":"Edlow AG, Bartz D. Hormonal contraceptive options for women with headache: a review of the evidence. Rev Obstet Gynecol. 2010;3:55\u201365.","journal-title":"Rev Obstet Gynecol"},{"key":"1421_CR43","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-017-0815-1","volume":"18","author":"S Sacco","year":"2017","unstructured":"Sacco S, Merki-Feld GS, \u00c6gidius KL, Bitzer J, Canonico M, Kurth T, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017;18:108.","journal-title":"J Headache Pain"},{"key":"1421_CR44","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/WNL.47.4.871","volume":"47","author":"S Silberstein","year":"1996","unstructured":"Silberstein S, Lipton R, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology. 1996;47:871\u20135.","journal-title":"Neurology"},{"key":"1421_CR45","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","volume":"48","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache J Head Face Pain. 2008;48:1157\u201368.","journal-title":"Headache J Head Face Pain"},{"key":"1421_CR46","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","volume":"13","author":"LM Bloudek","year":"2012","unstructured":"Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, et al. Cost of healthcare for patients with migraine in five European countries: Results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13:361\u201378.","journal-title":"J Headache Pain"},{"key":"1421_CR47","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/practneurol-2015-001167","volume":"15","author":"AJ Sinclair","year":"2015","unstructured":"Sinclair AJ, Sturrock A, Davies B, Matharu M. Headache management: pharmacological approaches. Pract Neurol. 2015;15:411\u201323.","journal-title":"Pract Neurol"},{"key":"1421_CR48","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.4103\/aian.AIAN_349_17","volume":"21","author":"DY-T Wei","year":"2018","unstructured":"Wei DY-T, Yuan Ong JJ, Goadsby PJ. Cluster headache: epidemiology, pathophysiology, clinical features, and diagnosis. Ann Indian Acad Neurol. 2018;21:S3\u2013S8.","journal-title":"Ann Indian Acad Neurol"},{"key":"1421_CR49","first-page":"S51","volume":"15","author":"G Lambru","year":"2012","unstructured":"Lambru G, Matharu MS. Trigeminal autonomic cephalalgias: a review of recent diagnostic, therapeutic and pathophysiological developments. Ann Indian Acad Neurol. 2012;15:S51\u2013S61.","journal-title":"Ann Indian Acad Neurol"},{"key":"1421_CR50","first-page":"12","volume":"14","author":"A Cohen","year":"2014","unstructured":"Cohen A. Trigeminal autonomic cephalagias\u2014a diagnostic and therapeutic overview. ACNR. 2014;14:12\u201315.","journal-title":"ACNR"},{"key":"1421_CR51","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1212\/01.wnl.0000174435.37184.c3","volume":"65","author":"KS Shindler","year":"2005","unstructured":"Shindler KS, Sankar PS, Volpe NJ, Piltz-Seymour JR. Intermittent headaches as the presenting sign of subacute angle-closure glaucoma. Neurology. 2005;65:757\u20138.","journal-title":"Neurology"},{"key":"1421_CR52","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/0883073811426502","volume":"27","author":"AA Gelfand","year":"2012","unstructured":"Gelfand AA, Gelfand JM, Prabakhar P, Goadsby PJ. Ophthalmoplegic \u201cmigraine\u201d or recurrent ophthalmoplegic cranial neuropathy: new cases and a systematic review. J Child Neurol. 2012;27:759\u201366.","journal-title":"J Child Neurol"},{"key":"1421_CR53","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/WNO.0b013e3182474548","volume":"32","author":"KB Digre","year":"2012","unstructured":"Digre KB, Brennan KC. Shedding light on photophobia. J Neuroophthalmol. 2012;32:68\u201381.","journal-title":"J Neuroophthalmol"},{"key":"1421_CR54","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.semarthrit.2016.11.002","volume":"46","author":"K Tuckwell","year":"2017","unstructured":"Tuckwell K, Collinson N, Dimonaco S, Klearman M, Blockmans D, Brouwer E, et al. Newly diagnosed vs. relapsing giant cell arteritis: baseline data from the GiACTA trial. Semin Arthritis Rheum. 2017;46:657\u201364.","journal-title":"Semin Arthritis Rheum"},{"key":"1421_CR55","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2169\/internalmedicine.50.5205","volume":"50","author":"N Imai","year":"2011","unstructured":"Imai N, Kuroda R, Konishi T, Serizawa M, Kobari M. Giant cell arteritis: clinical features of patients visiting a headache clinic in Japan. Intern Med . 2011;50:1679\u201382.","journal-title":"Intern Med"},{"key":"1421_CR56","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/bmj.1.6072.1355-b","volume":"1","author":"RV Jones","year":"1977","unstructured":"Jones RV. Unbearable headache of temporal arteritis. Br Med J. 1977;1:1355.","journal-title":"Br Med J"},{"key":"1421_CR57","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5114\/reum.2016.63663","volume":"54","author":"C Manzo","year":"2016","unstructured":"Manzo C. Widespread headache as the first clinical manifestation of giant cell arteritis in patients affected by polymyalgia rheumatica. Reumatologia. 2016;54:236\u20138.","journal-title":"Reumatologia"},{"key":"1421_CR58","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3899\/jrheum.141347","volume":"42","author":"TA Kermani","year":"2015","unstructured":"Kermani TA, Warrington KJ, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol. 2015;42:1213\u20137. https:\/\/doi.org\/10.3899\/jrheum.141347","journal-title":"J Rheumatol"},{"key":"1421_CR59","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11102-005-1050-3","volume":"7","author":"L Sibal","year":"2004","unstructured":"Sibal L, Ball SG, Connolly V, James RA, Kane P, Kelly WF, et al. Pituitary apoplexy: a review of clinical presentation, management and outcome in 45 cases. Pituitary. 2004;7:157\u201363.","journal-title":"Pituitary"},{"key":"1421_CR60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2265.2010.03913.x","volume":"74","author":"S Rajasekaran","year":"2011","unstructured":"Rajasekaran S, Vanderpump M, Baldeweg S, Drake W, Reddy N, Lanyon M, et al. UK guidelines for the management of pituitary apoplexy. Clin Endocrinol. 2011;74:9\u201320.","journal-title":"Clin Endocrinol"},{"key":"1421_CR61","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1210\/er.2015-1042","volume":"36","author":"C Briet","year":"2015","unstructured":"Briet C, Salenave S, Bonneville JF, Laws ER, Chanson P. Pituitary apoplexy. Endocr Rev. 2015;36:622\u201345.","journal-title":"Endocr Rev"},{"key":"1421_CR62","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1530\/EC-18-0255","volume":"7","author":"A Abbara","year":"2018","unstructured":"Abbara A, Clarke S, Eng PC, Milburn J, Joshi D, Comninos AN, et al. Clinical and biochemical characteristics of patients presenting with pituitary apoplexy. Endocr Connect. 2018;7:1058\u201366.","journal-title":"Endocr Connect"},{"key":"1421_CR63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clineuro.2006.01.006","volume":"109","author":"AS Dubuisson","year":"2007","unstructured":"Dubuisson AS, Beckers A, Stevenaert A. Classical pituitary tumour apoplexy: clinical features, management and outcomes in a series of 24 patients. Clin Neurol Neurosurg. 2007;109:63\u201370.","journal-title":"Clin Neurol Neurosurg"},{"key":"1421_CR64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1365-2265.1999.00754.x","volume":"51","author":"HS Randeva","year":"1999","unstructured":"Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA. Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol. 1999;51:181\u20138.","journal-title":"Clin Endocrinol"},{"key":"1421_CR65","first-page":"7124364","volume":"2018","author":"N Salehi","year":"2018","unstructured":"Salehi N, Firek A, Munir I. Pituitary apoplexy presenting as ophthalmoplegia and altered level of consciousness without headache. Case Rep. Endocrinol. 2018;2018:7124364.","journal-title":"Case Rep. Endocrinol"},{"key":"1421_CR66","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/01.wno.0000223270.01813.57","volume":"26","author":"RE Warwar","year":"2006","unstructured":"Warwar RE, Bhullar SS, Pelstring RJ, Fadell RJ. Sudden death from pituitary apoplexy in a patient presenting with an isolated sixth cranial nerve palsy. J Neuroophthalmol. 2006;26:95\u20137.","journal-title":"J Neuroophthalmol"},{"key":"1421_CR67","doi-asserted-by":"crossref","first-page":"219","DOI":"10.21037\/qims.2018.03.08","volume":"8","author":"P Goyal","year":"2018","unstructured":"Goyal P, Utz M, Gupta N, et al. Clinical and imaging features of pituitary apoplexy and role of imaging in differentiation of clinical mimics. Quant Imaging Med Surg. 2018;8:219\u201331.","journal-title":"Quant Imaging Med Surg"},{"key":"1421_CR68","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/archneur.1996.00550100033012","volume":"53","author":"JamesR Keane","year":"1996","unstructured":"Keane JamesR. Cavernous sinus syndrome: analysis of 151 cases. Arch Neurol. 1996;53:967\u201371.","journal-title":"Arch Neurol"},{"key":"1421_CR69","first-page":"39","volume":"5","author":"DC Stanton","year":"1999","unstructured":"Stanton DC, Kempers KG, Hendler BH, Cutilli BJ, Hurst RW. Posttraumatic carotid-cavernous sinus fistula. J Craniomaxillofac Trauma. 1999;5:39\u201344.","journal-title":"J Craniomaxillofac Trauma"},{"key":"1421_CR70","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/jnnp-2017-317440","volume":"89","author":"SP Mollan","year":"2018","unstructured":"Mollan SP, Davies B, Silver NC, Shaw S, Mallucci CL, Wakerley BR, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89:1088\u2013100.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1421_CR71","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1001\/jamaneurol.2019.1812","volume":"76","author":"NJ Adderley","year":"2019","unstructured":"Adderley NJ, Subramanian A, Nirantharakumar K, Yiangou A, Gokhale KM, Mollan SP, et al. Association between idiopathic intracranial hypertension and risk of cardiovascular diseases in women in the United Kingdom. JAMA Neurol. 2019;76:1088\u201398.","journal-title":"JAMA Neurol"},{"key":"1421_CR72","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41433-018-0238-5","volume":"33","author":"SP Mollan","year":"2019","unstructured":"Mollan SP, Aguiar M, Evison F, Frew E, Sinclair AJ. The expanding burden of idiopathic intracranial hypertension. Eye. 2019;33:478\u201385.","journal-title":"Eye"},{"key":"1421_CR73","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1756285616635987","volume":"9","author":"RH Jensen","year":"2016","unstructured":"Jensen RH, Radojicic A, Yri H. The diagnosis and management of idiopathic intracranial hypertension and the associated headache. Ther Adv Neurol Disord. 2016;9:317\u201326.","journal-title":"Ther Adv Neurol Disord"},{"key":"1421_CR74","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-015-0521-9","volume":"16","author":"Y Mulla","year":"2015","unstructured":"Mulla Y, Markey KA, Woolley RL, Patel S, Mollan SP, Sinclair AJ. Headache determines quality of life in idiopathic intracranial hypertension. J Headache Pain. 2015;16:521.","journal-title":"J Headache Pain"},{"key":"1421_CR75","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/head.13153","volume":"57","author":"DI Friedman","year":"2017","unstructured":"Friedman DI, Quiros PA, Subramanian PS, Mejico LJ, Gao S, McDermott M, et al. Headache in idiopathic intracranial hypertension: findings from the idiopathic intracranial hypertension treatment trial. Headache J Head Face Pain. 2017;57:1195\u2013205.","journal-title":"Headache J Head Face Pain"},{"key":"1421_CR76","doi-asserted-by":"crossref","first-page":"c2701","DOI":"10.1136\/bmj.c2701","volume":"341","author":"AJ Sinclair","year":"2010","unstructured":"Sinclair AJ, Burdon MA, Nightingale PG, Ball AK, Good P, Matthews TD, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ. 2010;341:c2701.","journal-title":"BMJ"},{"key":"1421_CR77","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40123-020-00296-0","volume":"9","author":"J Virdee","year":"2020","unstructured":"Virdee J, Larcombe S, Vijay V, Sinclair AJ, Dayan M, Mollan SP. Reviewing the recent developments in idiopathic intracranial hypertension. Ophthalmol Ther. 2020;9:767\u201381.","journal-title":"Ophthalmol Ther"},{"key":"1421_CR78","doi-asserted-by":"publisher","unstructured":"Yiangou A, Mitchell JL, Fisher C, Edwards J, Vijay V, Alimajstorovic Z, et al. Erenumab for headaches in idiopathic intracranial hypertension: a prospective open-label evaluation. Headache. 2020. https:\/\/doi.org\/10.1111\/head.14026.","DOI":"10.1111\/head.14026"},{"key":"1421_CR79","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01182-7","volume":"21","author":"A Yiangou","year":"2020","unstructured":"Yiangou A, Mitchell JL, Vijay V, Grech O, Bilton E, Lavery GG, et al. Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. J Headache Pain 2020;21:116.","journal-title":"J Headache Pain"},{"key":"1421_CR80","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10194-011-0388-3","volume":"12","author":"A Negro","year":"2011","unstructured":"Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12:593\u2013601.","journal-title":"J Headache Pain"},{"key":"1421_CR81","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1468-2982.2004.00691.x","volume":"24","author":"ME Bigal","year":"2004","unstructured":"Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre\u2014clinical characteristics and treatment outcomes. Cephalalgia. 2004;24:483\u201390.","journal-title":"Cephalalgia"},{"key":"1421_CR82","volume":"15","author":"JT Lai","year":"2014","unstructured":"Lai JT, Dereix JD, Ganepola RP, Nightingale PG, Markey KA, Aveyard PN, et al. Should we educate about the risks of medication overuse headache? J Headache Pain. 2014;15:10.","journal-title":"J Headache Pain"},{"key":"1421_CR83","unstructured":"BASH. Guidelines for all healthcare professionals in the diagnosis and management of migrane, tension-type, cluster and medication-overuse headache. The British Association for the Study of Headache guidelines, 3rd edn. Hull, 2010. https:\/\/www.bash.org.uk\/wp-content\/uploads\/2012\/07\/10102-BASH-Guidelines-update-2_v5-1-indd.pdf."},{"key":"1421_CR84","doi-asserted-by":"crossref","DOI":"10.1186\/s40064-016-2211-8","volume":"5","author":"F Antonaci","year":"2016","unstructured":"Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus. 2016;5:637.","journal-title":"Springerplus"},{"key":"1421_CR85","doi-asserted-by":"crossref","first-page":"g2285","DOI":"10.1136\/bmj.g2285","volume":"348","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim T, Becker WJ. Triptans for symptomatic treatment of migraine headache. BMJ. 2014;348:g2285.","journal-title":"BMJ"},{"key":"1421_CR86","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N. Engl J Med. 2019;381:142\u20139.","journal-title":"N. Engl J Med"},{"key":"1421_CR87","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322:1887\u201398.","journal-title":"JAMA"},{"key":"1421_CR88","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142:1894\u2013904.","journal-title":"Brain"},{"key":"1421_CR89","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1526-4637.2006.00216.x","volume":"7","author":"VK Gupta","year":"2006","unstructured":"Gupta VK. Botulinum toxin\u2014a treatment for migraine? A systematic review. Pain Med. 2006;7:386\u201394.","journal-title":"Pain Med"},{"key":"1421_CR90","unstructured":"National Institute for Health and Care Excellence. Botulinum to toxin type A for the prevention of headaches in adults with chronic migraine. [London]: NICE, 2012. (Technology appraisal guidance [TA260]). https:\/\/www.nice.org.uk\/guidance\/ta260."},{"key":"1421_CR91","doi-asserted-by":"publisher","unstructured":"Herd C, Tomlinson C, Rick C, Scotton W, Edwards J, Ives N, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Datab Syst Rev. 2018; 6: CD011616. https:\/\/www.cochranelibrary.com\/cdsr\/https:\/\/doi.org\/10.1002\/14651858.CD011616.pub2\/epdf\/full.","DOI":"10.1002\/14651858.CD011616"},{"key":"1421_CR92","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-019-0976-1","volume":"20","author":"F Ahmed","year":"2019","unstructured":"Ahmed F, Gaul C, Garc\u00eda-Monc\u00f3 JC, Sommer K, Martelletti P. REPOSE Principal Investigators. An open-label prospective study of the real-life use of onabotulinumtoxin A for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019;20:26.","journal-title":"J Headache Pain"},{"key":"1421_CR93","doi-asserted-by":"crossref","DOI":"10.1186\/1129-2377-15-54","volume":"15","author":"M Khalil","year":"2014","unstructured":"Khalil M, Zafar HW, Quarshie V, Ahmed F. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K. J Headache Pain. 2014;15:54.","journal-title":"J Headache Pain"},{"key":"1421_CR94","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/practneurol-2015-001298","volume":"16","author":"S Miller","year":"2016","unstructured":"Miller S, Sinclair AJ, Davies B, Matharu M. Neurostimulation in the treatment of primary headaches. Pract Neurol 2016;16:362\u201375.","journal-title":"Pract Neurol"},{"key":"1421_CR95","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2147\/NDT.S3497","volume":"4","author":"D D\u2019Amico","year":"2008","unstructured":"D\u2019Amico D, J Tepper S. Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat. 2008;4:1155\u201367. https:\/\/doi.org\/10.2147\/NDT.S3497","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1421_CR96","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0304-3940(85)90296-4","volume":"62","author":"R Uddman","year":"1985","unstructured":"Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: Trigeminal origin and co-existence with substance P. Neurosci Lett. 1985;62:131\u20136.","journal-title":"Neurosci Lett"},{"key":"1421_CR97","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","volume":"350","author":"J Olesen","year":"2004","unstructured":"Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl J Med. 2004;350:1104\u201310.","journal-title":"N. Engl J Med"},{"key":"1421_CR98","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3389\/fphar.2019.00795","volume":"10","author":"F Xu","year":"2019","unstructured":"Xu F, Sun W. Network meta-analysis of calcitonin gene-related peptide receptor antagonists for the acute treatment of migraine. Front Pharm. 2019;10:795.","journal-title":"Front Pharm"},{"key":"1421_CR99","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0333102417741297","volume":"39","author":"S Khan","year":"2019","unstructured":"Khan S, Olesen A, Ashina M. CGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data. Cephalalgia. 2019;39:374\u201389.","journal-title":"Cephalalgia"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41433-021-01421-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-021-01421-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-021-01421-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:12:58Z","timestamp":1684617178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01421-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":99,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1421"],"URL":"https:\/\/doi.org\/10.1038\/s41433-021-01421-4","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"5 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SPM\u2014Novartis, speaker fees (2020). Invex therapeutics, advisory board (2020). ASJ\u2014Novartis and Allergan Advisory board. Speaker fees Novartis. Invex therapeutics, company director with salary and stock options (2019, 2020). No other authors contributing have a conflict of interest in the subject matter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}